Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia.
Tantravahi SK, Szankasi P, Khorashad JS, Dao KH, Kovacsovics T, Kelley TW, Deininger MW. Tantravahi SK, et al. Among authors: szankasi p. Leuk Lymphoma. 2016 Oct;57(10):2441-4. doi: 10.3109/10428194.2016.1138295. Epub 2016 Feb 8. Leuk Lymphoma. 2016. PMID: 26752680 Free PMC article. Clinical Trial. No abstract available.
Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib.
Qiang W, Antelope O, Zabriskie MS, Pomicter AD, Vellore NA, Szankasi P, Rea D, Cayuela JM, Kelley TW, Deininger MW, O'Hare T. Qiang W, et al. Among authors: szankasi p. Leukemia. 2017 Dec;31(12):2844-2847. doi: 10.1038/leu.2017.264. Epub 2017 Aug 18. Leukemia. 2017. PMID: 28819281 Free PMC article. Clinical Trial. No abstract available.
BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.
Khorashad JS, Kelley TW, Szankasi P, Mason CC, Soverini S, Adrian LT, Eide CA, Zabriskie MS, Lange T, Estrada JC, Pomicter AD, Eiring AM, Kraft IL, Anderson DJ, Gu Z, Alikian M, Reid AG, Foroni L, Marin D, Druker BJ, O'Hare T, Deininger MW. Khorashad JS, et al. Among authors: szankasi p. Blood. 2013 Jan 17;121(3):489-98. doi: 10.1182/blood-2012-05-431379. Epub 2012 Dec 5. Blood. 2013. PMID: 23223358 Free PMC article.
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.
Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H, Schultz AR, Clair P, Bowler AD, Pomicter AD, Yan D, Senina AV, Qiang W, Kelley TW, Szankasi P, Heinrich MC, Tyner JW, Rea D, Cayuela JM, Kim DW, Tognon CE, O'Hare T, Druker BJ, Deininger MW. Eide CA, et al. Among authors: szankasi p. Cancer Cell. 2019 Oct 14;36(4):431-443.e5. doi: 10.1016/j.ccell.2019.08.004. Epub 2019 Sep 19. Cancer Cell. 2019. PMID: 31543464 Free PMC article.
Molecular genetic biomarkers in myeloid malignancies.
Matynia AP, Szankasi P, Shen W, Kelley TW. Matynia AP, et al. Among authors: szankasi p. Arch Pathol Lab Med. 2015 May;139(5):594-601. doi: 10.5858/arpa.2014-0096-RA. Epub 2014 Aug 25. Arch Pathol Lab Med. 2015. PMID: 25152312 Free article. Review.
46 results